Identification and characterisation of a dual GLP-1/GLP-2 agonist peptide, HTL0030023 using structure based drug design

By Rie Suzuki | Mar 29, 2022

Rie Suzuki, Director Translational Sciences at Sosei Heptares presented a poster at the American Chemical Society (ACS) Spring 2022 meeting, describing the design strategy and pharmacodynamic evaluation of HTL0030023, a novel GLP-1/ GLP-2 agonist. 



  • Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake. 
  • Using SBDD, a novel peptide agonist with pharmacological activity at GLP-1 and GLP-2 receptors was designed to explore the hypothesis that peptides with dual pharmacology provide benefits on nutrient absorption and intestinal function.  HTL0030023 was shown to display improved pharmacokinetic and pharmacodynamic properties compared to the clinical GLP2 agent, teduglutide. 
  • The unique pharmacology of HTL0030023 may offer therapeutic opportunity in a number of diseases including short bowel syndrome and metabolic conditions such as Non alcoholic steatohepatitis (NASH).  

View Poster